Cell Biosciences Acquires Protein Forest

SANTA CLARA, California, December 7 - Cell Biosciences, Inc. today announced that it has acquired Protein
Forest, Inc. of Lexington, Massachusetts, a leader in sample preparation
technology for proteomic analysis and biomarker discovery. This strategic
acquisition adds Protein Forest's novel digital ProteomeChip(TM) product line
to Cell Biosciences' expanding portfolio of innovative products for protein
analysis.

Protein Forest, founded in 2002, pioneered a new technology for rapid,
highly reproducible protein fractionation of complex biological samples - an
important prerequisite step for quantitative proteomics measurements. The
technology can be used as a sample preparation front-end for many protein
analysis techniques, including western blot analysis, mass spectrometry, and
the Cell Biosciences' nanoproteomic platforms. The digital ProteomeChip
product line includes instrumentation, software, reagents, and proprietary
consumables.

Cell Biosciences is a private life sciences company focused on defining
the future of protein analysis. The company's products include novel
nanofluidic assay systems for ultrasensitive protein analysis, and a complete
line of leading digital imaging systems for proteomic and genomic research.
Cell Biosciences has approximately 100 employees in North America, Europe and
Asia, and its products are sold in more than 40 countries.

Commenting on the transaction, Tim Harkness, President and Chief
Executive Officer of Cell Biosciences, said, "This acquisition adds an
exciting sample preparation product line to our growing protein analysis
business. The lack of reproducible sample preparation has become a serious
problem for proteomics researchers. We believe that the digital ProteomeChip
products represent a powerful solution for this market need. The digital
ProteomeChip product line fits perfectly with our strategic plan and will be
leveraged immediately by our global distribution organization."

In connection with the all-stock acquisition, Cell Biosciences raised an
additional US$4 million in an equity financing, led by Novo A/S.

ABOUT CELL BIOSCIENCES

Cell Biosciences is a private life sciences company focused on defining
the future of protein analysis. The Company develops instrumentation systems,
sample preparation systems, software and assay products that drive
discoveries in fields ranging from fundamental protein research to biomarker
discovery and personalized medicine. With an installed base of over 10,000
systems, its customers include leading research institutions, pharmaceutical
and biotechnology companies worldwide. Cell Biosciences is headquartered in
Santa Clara, California. For more information, visit www.cellbiosciences.com.

Tim Harkness, CEO of Cell Biosciences, Inc., +1-408-510-5501, tharkness at cellbiosciences.com